Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of evogliptin on coronary artery plaque in patients with type 2 diabetes mellitus
KCT0005239Phase 4Not yet recruiting
- Sponsor
- Dong-A ST
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of DA5221-B2 in type 2 diabetes mellitus (T2DM), coronary arteriosclerosis, sponsored by Dong-A ST. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosis
Beyond the preview
Go deeper on KCT0005239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005239.